Harmony Biosciences Holdings, Inc.·4

Apr 6, 4:14 PM ET

Ignelzi Troy A. 4

4 · Harmony Biosciences Holdings, Inc. · Filed Apr 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Harmony Biosciences Director Troy A. Ignelzi Receives Award

What Happened Troy A. Ignelzi, a director of Harmony Biosciences Holdings, Inc. (HRMY), was granted 17,710 derivative shares (a stock option award) on April 2, 2026. The Form 4 reports an acquisition price of $0.00 and a reported value of $0. This was an equity award (grant), not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-04-02; Form 4 filed 2026-04-06 (timely — within the 2 business-day window).
  • Amount: 17,710 derivative shares (stock option grant) reported at $0.00.
  • Shares owned after transaction: not specified in the filing.
  • Footnote: The stock option vests in 36 equal monthly installments beginning May 2, 2026.
  • Exercise price or other option terms beyond vesting schedule are not disclosed on this Form 4.

Context This filing documents an option grant to a director. Option grants vesting over time are common long-term compensation and do not represent an immediate purchase or sale of stock. Because the award vests monthly over three years, any future exercise or sale would be reported in subsequent filings.

Insider Transaction Report

Form 4
Period: 2026-04-02
Transactions
  • Award

    Stock Option

    [F1]
    2026-04-02+17,71017,710 total
    Exercise: $27.74Exp: 2036-04-02Common Stock (17,710 underlying)
Footnotes (1)
  • [F1]The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026.
Signature
/s/ Christian Ulrich, Attorney-in-Fact|2026-04-06

Documents

1 file
  • 4
    form4-04062026_080459.xmlPrimary